[Elsevier] Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: 52-week results from the randomised, double-blind, placebo-controlled phase 3 POETYK PsA-1 trial |
|
This post will be closed automatically in 2026-08-25 15:47
Reward10points
|
post
reply
points
2811
10
Data-augmented SOH estimation for lithium-ion batteries under small-sample conditions: A hybrid STL-transformer-TimesNet approach
10
Steel benchmark frames for structural analysis and validation studies: Finite element models and numerical simulation data
30
AI-based geological subsurface reconstruction using sparse convolutional autoencoders
10
A shallow mirror transformer for subject-independent motor imagery BCI
10
DAEEGViT: A domain adaptive vision transformer framework for EEG cognitive state identification
